We are live on
!
Find out more
First Manhattan Portfolio holdings
AUM
$36.1B
1-Year Est. Return
11.5%
This Fund
S&P 500
This Quarter
Est. Return
+9.64%
1 Year Est. Return
+11.5%
3 Year Est. Return
+74.65%
5 Year Est. Return
+103.66%
10 Year Est. Return
+354.63%
AUM
$27.3B
AUM Growth
+$1.22B
(+4.7%)
Cap. Flow
-$932M
Cap. Flow
% of AUM
-3.41%
Top 10 Holdings %
Top 10 Hldgs %
60.57%
Holding
1,588
New
70
Increased
176
Reduced
495
Closed
161
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Thermo Fisher Scientific
TMO
|
+$128M |
| 2 |
ATVI
Activision Blizzard
ATVI
|
+$67.4M |
| 3 |
XIFR
XPLR Infrastructure LP
XIFR
|
+$63.8M |
| 4 |
UnitedHealth
UNH
|
+$57.4M |
| 5 |
Danaher
DHR
|
+$24.8M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Berkshire Hathaway Class A
BRK.A
|
+$760M |
| 2 |
Amazon
AMZN
|
+$68.5M |
| 3 |
AbbVie
ABBV
|
+$54.2M |
| 4 |
PPLI
People Inc
PPLI
|
+$36.8M |
| 5 |
PNC Financial Services
PNC
|
+$29.8M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Financials | 44.09% |
| 2 | Technology | 18.28% |
| 3 | Healthcare | 10.34% |
| 4 | Consumer Discretionary | 7.89% |
| 5 | Communication Services | 5.03% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
76
Graco
GGG
$12.9B
| $31.1M | 0.11% |
382,502
-13,305
| -3% | -$1.03M |
|
77
United Therapeutics
UTHR
$26.4B
| $30.8M | 0.11% |
139,400
| – | – |
|
78
AB InBev
BUD
$155B
| $29.5M | 0.11% |
520,187
-35,862
| -6% | -$2.17M |
|
79
Eli Lilly
LLY
$1.06T
| $28.5M | 0.1% |
60,785
-23,535
| -28% | -$9.87M |
|
80
Amgen
AMGN
$201B
| $28.5M | 0.1% |
129,964
-5,844
| -4% | -$1.36M |
|
81
United Parcel Service
UPS
$97B
| $28.4M | 0.1% |
158,687
-3,926
| -2% | -$697K |
|
|
SCHW
82
Charles Schwab
SCHW
$177B
| $27.8M | 0.1% |
490,270
+12,175
| +3% | +$638K |
|
83
American Water Works
AWK
$26.2B
| $27.2M | 0.1% |
190,391
-2,910
| -2% | -$427K |
|
84
Hilton Worldwide
HLT
$72.9B
| $26.4M | 0.1% |
181,704
+63
| +0% | +$8.97K |
|
85
Merck
MRK
$322B
| $25.6M | 0.09% |
222,174
-6,889
| -3% | -$782K |
|
86
PepsiCo
PEP
$184B
| $23.6M | 0.09% |
127,284
-12,645
| -9% | -$2.36M |
|
87
Diageo
DEO
$45.7B
| $23.1M | 0.08% |
133,444
-18,307
| -12% | -$3.27M |
|
88
Vanguard High Dividend Yield ETF
VYM
$80.6B
| $22.9M | 0.08% |
216,252
-2,000
| -0.9% | -$210K |
|
89
Nice
NICE
$5.09B
| $22.6M | 0.08% |
127,284
+16,055
| +14% | +$3.31M |
|
90
Wells Fargo 7.5% Non Cumv Perp Conv
WFC.PRL
$4.66B
| $21.8M | 0.08% |
18,912
+3,636
| +24% | +$4.19M |
|
|
91
Wells Fargo
WFC
$261B
| $20.8M | 0.08% |
488,505
-30,060
| -6% | -$1.21M |
|
92
Ball Corp
BALL
$16.6B
| $20.7M | 0.08% |
396,634
+286,223
| +259% | +$15.5M |
|
93
ExxonMobil
XOM
$650B
| $20.6M | 0.08% |
192,085
-25,441
| -12% | -$2.78M |
|
94
Brookfield Renewable
BEP
$10B
| $19.8M | 0.07% |
672,006
-302
| -0% | -$9.29K |
|
95
Sweetgreen
SG
$718M
| $18.8M | 0.07% |
1,466,515
+204,250
| +16% | +$1.89M |
|
96
TE Connectivity
TEL
$58B
| $18.7M | 0.07% |
133,596
-1,487
| -1% | -$188K |
|
97
Booking.com
BKNG
$134B
| $18.7M | 0.07% |
172,700
-350
| -0.2% | -$37K |
|
98
Bilibili
BILI
$7.32B
| $18.6M | 0.07% |
1,231,794
| – | – |
|
99
Boeing
BA
$165B
| $18.3M | 0.07% |
86,649
-1,695
| -2% | -$352K |
|
100
Nutrien
NTR
$32.9B
| $18M | 0.07% |
305,275
-12,625
| -4% | -$804K |
|
Similar funds
SAM
First Manhattan's Q2 2023 Portfolio in Review
As of Q2 2023, First Manhattan held 1,588 positions worth $27.3B, up 4.7% from $26.1B the previous quarter. Its ten largest holdings account for 61% of the portfolio.
First Manhattan withdrew a net $932M in Q2 2023, closing 161 positions and reducing 495 holdings. Its most notable exit was Enanta Pharmaceuticals, an estimated $10.7M position sold in full.
By sector, the portfolio is most concentrated in Financials at 44% of assets, down from 45% a quarter earlier, followed by Technology and Healthcare.
Against the trend, First Manhattan opened a new position in Mersana Therapeutics worth $1.87M.
- First Manhattan's largest Q2 2023 buy was Mersana Therapeutics: 22,784 shares worth $1.87M.
- First Manhattan added most to Thermo Fisher Scientific in Q2 2023, an estimated $128M increase.
- First Manhattan's biggest Q2 2023 reduction was Berkshire Hathaway Class A, cutting an estimated $760M.
- First Manhattan fully exited Enanta Pharmaceuticals in Q2 2023, selling an estimated $10.7M.
- First Manhattan's ten largest holdings make up 61% of its $27.3B portfolio in Q2 2023.
- First Manhattan opened 70 new positions and closed 161 in Q2 2023.
- First Manhattan's portfolio value rose 4.7% quarter-over-quarter to $27.3B.
Based on First Manhattan's 13F filing for Q2 2023, filed 14 Aug 2023.